Get the Stockscreener App
14.36
0.63%
0.09
After Hours:
14.16
-0.20
-1.39%
Takeda Pharmaceutical Co Adr stock is traded at $14.36, with a volume of 4.39M.
It is up +0.63% in the last 24 hours and up +0.14% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$14.27
Open:
$14.5
24h Volume:
4.39M
Relative Volume:
2.30
Market Cap:
$48.22B
Revenue:
$30.08B
Net Income/Loss:
$710.16M
P/E Ratio:
65.81
EPS:
0.2182
Net Cash Flow:
$4.45B
1W Performance:
-6.27%
1M Performance:
+0.14%
6M Performance:
+4.21%
1Y Performance:
+7.40%
1-Day Range:
$14.34
$14.57
1-Week Range:
$14.21
$15.43
52-Week Range:
$12.57
$15.43
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Klaviyo Inc (KVYO) Stock: The Story of a 52-Week Stock Range - investchronicle.com
You might want to take a look at Denison Mines Corp (DNN) now - Sete News
A Look at Cousins Properties Inc (CUZ) Shares in the Recent Past Indicates Growth - Sete News
A better buy-in window may exist right now for Cheesecake Factory Inc (CAKE) - Sete News
Stocks of CN Energy Group Inc (CNEY) are poised to climb above their peers - Sete News
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - knoxdaily.com
Cintas Corporation [CTAS] Insider Activity: An Update for Investors - knoxdaily.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
Morgan Stanley lifts Takeda stock rating, raises target to JPY5,500 - Investing.com
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo
PD Stock on the Rise: A Promising Investment - The InvestChronicle
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
Vyvanse Leaks: Beyond The Headlines - truthorfiction.com
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):